Press release
Absci Reports New Human Ex Vivo Data Demonstrating That ABS-201™ Stimulates Hair Growth and Regenerates Stem Cell Niche to Potentially Reverse Follicle Miniaturization
Inhibiting prolactin receptor (PRLR) signaling with the ABS-201 anti-PRLR antibody promotes human hair follicle growth ex vivo Human ex vivo data validate
About this update from Absci Corporation
[{"type":"text","content":"Inhibiting prolactin receptor (PRLR) signaling with the ABS-201 anti-PRLR antibody promotes human hair follicle growth ex vivo Human ex vivo data validate ABS-201’s potential to reverse follicular miniaturization and drive vellus-to-terminal hair regeneration by demonstrating that it prolongs anagen, stimulates keratin synthesis, and modulates the stem cell niche Full dataset will be presented during today’s ABS-201 Key Opinion Leader (KOL) seminar VANCOUVER, Wash. and NEW YORK, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics with generative AI, today unveiled new preclinical data for ABS-201, an AI-designed antibody targeting the prolactin receptor. The data, generated using translational human ex vivo scalp models, demonstrate that ABS-201 effectively stimulates hair growth by regenerating the stem cell niche as well as promoting additional key growth modulators. The findings will be presented today at Absci’s ABS-201 KOL seminar – interested parties may register for the virtual event via this link. “Today’s standard treatment options for androgenetic alopecia (AGA) do not target one of its root causes, the reduced capacity of hair follicle stem cells to generate progenitor cells, and largely ignore the role of other hormones than androgens in this form of hair loss,” said Professor Ralf Paus, M.D., D.Sc., F.R.S.B., Research Professor of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine. “Our study provides the first evidence that antagonizing prolactin signaling with ABS-201 could open a radically new chapter in future AGA management.” Key Data Highlights These studies were conducted in organ-cultured, full-thickness human scalp skin derived from male donors, a model considered highly predictive of clinical response, to assess the efficacy of ABS-201 in modulating prolactin-induced transition from the anagen (active growth) phase to the catagen (regression/apoptosis) phase. Mechanistically, ABS-201 treatment significantly inhibited the PRLR signaling pathway (STAT5 phosphorylation). This inhibition correlated with: Prolongation of Anagen and Restoration of Growth Signaling: ABS-201 prolongs anagen by blocking catagen, promoting hair matrix keratinocyte proliferation, and increasing the hair follicl...